ResApp Health


>


Company Announcements:
(reported by the Company)
Elevator Pitch:

ResApp is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.

We will provide telehealth companies with point of care diagnostic solutions that can be easily integrated into their platforms.

We are working on apps to provide instant clinical quality diagnostic tests and management tools directly to consumers and healthcare providers.

Category: Consumer goods, Health & biotech
URL: http://www.resapphealth.com.au/
Operational Status: Active
ASX Listing Code (if applicable): RAP
Year of Commencement:
Address:

Level 24, 44 St Georges Terrace
Perth, WA 6000

State: Western Australia
Overseas Operations:
Twitter:
Facebook:
Linkedin: https://www.linkedin.com/company/resapp-health
Key Personnel:
Awards won:
Current Period Rank:



WA Annual Rank 2016: 4

Milestones:

    January, 2018

    Demonstrated succes in diagnosing chronic obstructive pulmonary disease and aggravations of COPD


    Appointed Nathan Buzza as non-executive director


    August, 2017

    Appointed Dr Philip Currie to its scientific advisory board


    April, 2017

    Signed a licensing agreement with UniQuest, the main commercialization company of The University of Queensland


    November, 2016

    Received its first institutional review board (IRB) approval for the SMARTCOUGH-C study


    October, 2016

    Presented at Tech23 2016 in Sydney


    Received its first institutional review board approval for its SMARTCOUGH-C study


    Won the Innovation Excellence Award at Tech 23


Funding:

    August, 2017

    Received $516k tax refund from R&D tax incentive


Company News:

NOTE: Company News, Milestones and Funding are as collected by Techboard as part of our Monthly Startup Ranking

Amount Seeking:
Type of capital raise:
Pre-money valuation:
ESIC Status:
ESIC Upload:
Future Intentions:
Investment Video:
Investment Pitchdeck:
Investment URL:
Investment Phone: Investment phone:
Investment Email:

Leave a Reply